An antibiotic would be able to reduce the spread of gonorrhea, syphilis and chlamydia after unprotected sex
For centuries there has always been a warning about the different diseases that can be sexually transmitted if proper care is not taken. However, and so that it is not only on alert, medicine is constantly searching to reduce diseases and, to the best extent possible, eradicate them.
Among the latest discoveries in this regard, the 24th International Conference on HIV/AIDS, held in the city of Montreal, Canada, a group of scientific researchers presented the results of a study on an antibiotic that reduces the spread of three sexually transmitted diseases .
It is the name of the protagonist and revolutionary medicine that, according to the results of its analysis, reduced the rates of chlamydia and gonorrhea in men who have sex with men by 60%, while in syphilis, although the percentage was not specified, it would be much more effective.
Annie Luetkemeyer, study leader and fellow at the University of California, San Francisco, said: “We now have two studies that support the use of doxycycline as PEP (post-exposure prophylaxis) in men who have sex with men.” She also specified that this antibiotic, taken after having unprotected sex (without a condom), can drastically reduce the spread of these three bacterial sexually transmitted diseases in high-risk groups, that is, people with comorbidities and autoimmune diseases.
The investigation was generated due to the latest statistics from the World Health Organization (WHO) that warn that the rates of sexually transmitted diseases have increased in recent years, particularly among homosexuals, who have reduced the use of condoms since the arrival of HIV Pre-Exposure Prophylaxis (PrEP) pills, a medication that blocks the ability of the virus to start an infection.
The specialists had about 500 people from the cities of San Francisco and Seattle, United States, mostly gay (including some trans women and people of diverse gender), who were monitored every three months. Among them, some were taking PrEP against HIV, while others were carriers of the Human Immunodeficiency Virus, and in both groups, about two-thirds received doxycycline and one-third did not.
The pill, at a 200-milligram dose, was administered within three days of unprotected sexual exposure, and participants could continue taking it as needed, depending on how much sexual contact they had. In this way, the intervention reduced the incidence of Sexually Transmitted Diseases by 62% in the group living with HIV and by 66% in the group taking PrEP against the Human Immunodeficiency Virus, while the effects Side effects were mild and adherence levels remained high.